Navigation Links
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Date:2/6/2009

TITUSVILLE, N.J., Feb. 6 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced that the company has submitted multiple applications to the U.S. Food and Drug Administration (FDA) which, if approved, would broaden treatment options for patients diagnosed with schizophrenia or schizoaffective disorder.

Earlier this week, the company submitted its response to the FDA complete response letter for paliperidone palmitate, received in August 2008. Paliperidone palmitate is an investigational once-monthly atypical antipsychotic injection which, if approved, will be indicated for the acute and maintenance treatment of schizophrenia.

The company also submitted two supplemental new drug applications (sNDAs) to the FDA requesting approval for the use of INVEGA tablets for the treatment of schizoaffective disorder as monotherapy and for use in combination with antidepressants and/or mood stabilizers. The sNDA submissions include data from two international, 6-week double-blind placebo-controlled studies that evaluated the efficacy and safety of INVEGA in patients with schizoaffective disorder. If approved by the FDA, INVEGA would be the only medication indicated to treat the condition.

Patients with schizoaffective disorder experience the psychotic symptoms of schizophrenia, such as hallucinations or delusions, as well as mania and/or depression. Because of the similarity in symptoms, schizoaffective disorder is sometimes misdiagnosed as schizophrenia or bipolar disorder. For patients who frequently use mental health services, schizophrenia and schizoaffective disorder may account for approximately 32% and 24% of cases respectively.(i)

INVEGA, an atypical antipsychotic medication, was first approved in the U.S. in December 2006 and is marketed by Janssen. It is approved for the acute and maintenance treatment of schizophrenia in the U.S. an
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD)
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... NEWS, Va. , Aug. 3, 2015 /PRNewswire/ ... be joining Orthopaedic & Spine Center ... them to manage their chronic pain through psychological ... Robinson is a Fellowship-trained, certified medical psychologist ... pain medicine. His vast experience ranges from assessment ...
(Date:8/3/2015)... , Aug. 3, 2015  BioElectronics Corporation (OTC Pink: ... management, announced that Andrew J. Whelan , President ... his program "On Business" at 9am EDT on Wednesday, ... live, tune to: http://tunein.com/radio/Money-Matters-Boston-1120-s27548/ ... the exceptional acceptance the company,s flagship product, ActiPatch Therapy, ...
(Date:8/3/2015)... , Aug. 3, 2015  CytomX, a biopharmaceutical ... cancer, today announced the promotion of several members ... Ray , who previously served as vice president ... promoted to senior vice president of corporate development ... held positions as the vice president of business ...
Breaking Medicine Technology:Orthopaedic & Spine Center Introduces New Pain Psychologist 2UpTick News Wire Radio Show Will Interview BioElectronics' CEO Andrew Whelan 2CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3
... Radioactive Microspheres in... -- ROME, August 19, 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... Reportlinker.com announces that a new market research ... Advances in Large Scale BioManufacturing and Scale-Up ... A Comprehensive Study of ... This new ASM study provides a clear view ...
Cached Medicine Technology:Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 2Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 3Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 4Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 5Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 6Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 7Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 8Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 9Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 2Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED 3
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale Capital ... announced the closing of a $118 million FHA-insured loan modification refinancing for Johnston ... Smithfield and Clayton, North Carolina. JHSC is a joint venture of Johnston ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Scale-up Online Seminar featuring researchers from Lubrizol, Pfizer, and Merck. This ... EDT. , Process development project timelines often require informed decisions with limited process ...
(Date:8/4/2015)... Washington, DC (PRWEB) , ... August 04, 2015 , ... ... Services, Inc.’s (AIS) in-house research team, can now be accessed at http://www.AISHealth.com . ... in AIS’s Directory of Health Plans: 2015, the tables and charts on the website’s ...
(Date:8/4/2015)... ... August 04, 2015 , ... Half of consumers ... is board-certified is increasingly influential in their choice of practitioner, according to new ... Consumer Survey on Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental Trading Company, Inc., the ... and school supplies, has developed engaging and affordable teacher supplies based on the ... student rewards, classroom decorations, crafts and educational resources featuring Carle’s vibrant illustrations and ...
Breaking Medicine News(10 mins):Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:Atlantic Information Services Website Offers Up-to-Date U.S. Health Plan Enrollment Data 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3
... appearance of a cold sore is,a sign that your ... emerge, according to John Sherman, ND, noted naturopathic,physician and ... 80% and 90% of the adult population have the ... Dr. Sherman, who,is the author of The Complete Botanical ...
... Patient safety incidents cost the federal Medicare ... preventable deaths during 2004 through 2006, according to ... Study. HealthGrades, analysis of 41 million Medicare patient ... had, on average, a 43 percent lower chance ...
... WALTHAM, Mass., April 7, 2008 Repligen,Corporation (Nasdaq: ... and,Chief Executive Officer, Walter C. Herlihy, Ph.D., will host ... at 9:00 a.m. EDT, to provide,an update on the ... Thomson/CCBN and can be accessed via,Repligen,s website at ...
... from China is no cause for alarm , , MONDAY, ... probable case of human-to-human transmission of bird flu in ... that there,s a genetic component to human-to-human transmission of ... "This suggests that there,s some genetic component to resistance ...
... ALB ) will hold its quarterly conference call to ... ET., This call is being webcast by Thomson/CCBN and ... in the Investor,Information section., To listen ... In # 800-591-6942 International Dial In ...
... April 7, 2008 American Media, Inc. (AMI),today ... corporate website certain,information currently required to be disclosed ... its amended Senior Secured Credit Agreement., The ... certain key magazine titles during the period April ...
Cached Medicine News:Health News:A Cold Sore Is Often A Warning Sign of Deeper Health Issues, Expert Says 2Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 2Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 3Health News:Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study 4Health News:Repligen Announces Conference Call to Update Orencia(R) Lawsuit 2Health News:Repligen Announces Conference Call to Update Orencia(R) Lawsuit 3Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 2Health News:Probable Case of Human-to-Human Bird Flu Transmission Reported 3Health News:Albemarle Corporation's First Quarter 2008 Earnings Conference Call To Be Held April 22, 2008 at 8:00am ET 2
... This therapeutic system is ... patient in mind. As ... and ongoing therapy, SONOCUR ... and effective therapy. Plus, ...
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... only one of the most modern lithotripters available ... from being designed for the treatment of the ... the MODULITH SLX can also be employed for ... equally suitable for the treatment of gallstones or ...
... The MINILITH SL1 developed by STORZ MEDICAL ... extensive experience in the field of kidney ... the specific requirements to be met by ... as has been outlined above. The MINILITH ...
Medicine Products: